Amgen — May 1, 2025 release

Reconciliation of GAAP EPS Guidance to Non-GAAP EPS Guidance for the Year Ending December 31, 2025 (Unaudited) GAAP diluted EPS guidance $ 12.21  — $ 13.46  Known adjustments to arrive at non-GAAP*: Acquisition-related expenses (a) 8.27  — 8.32  Impairment of intangible assets (b) 1.29 Net gains from equity investments (1.87) Other 0.05 Non-GAAP diluted EPS guidance $ 20.00  — $ 21.20  * The known adjustments are presented net of their related tax impact, which amount to approximately $1.77 per share. (a) The adjustments primarily include noncash amortization of intangible assets and fair value step-up of inventory acquired in business acquisitions. (b) The adjustment relates to the Otezla ® intangible asset impairment charge recorded during the first quarter of 2025. Our GAAP diluted EPS guidance does not include the effect of GAAP adjustments triggered by events that may occur subsequent to this press release such as acquisitions, asset impairments, litigation, changes in fair value of our contingent consideration obligations and changes in fair value of our equity investments. The stated guidance also includes the estimated impact of implemented tariffs, but does not account for any tariffs that could be implemented in the future, including potential sector-specific tariffs. Reconciliation of GAAP Tax Rate Guidance to Non-GAAP Tax Rate Guidance for the Year Ending December 31, 2025 (Unaudited) GAAP tax rate guidance 11.0  % — 12.5  % Tax rate of known adjustments discussed above 3.5  % Non-GAAP tax rate guidance 14.5  % — 16.0  %